ArticleACS medicinal chemistry letters2026
Discovery of JH-XIII-05-01, a First-in-Class Dual IRAK1/IRAK4 Degrader for MYD88 Mutant Lymphomas.
Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activating MYD88 mutations promote pro-survival signaling through divergent HCK/BTK and IRAK1/IRAK4 pathways, and persistent IRAK signaling may contribute to incomplete responses to BTK inhibitors. Here, we show that IRAK1 or IRAK4 knockdown reduced NFKB signaling and impaired MYD88 mutant lymphoma cell survival but, unexpectedly, enhanced ERK1/2 signaling, which was blocked by HCK/BTK inhibition. Knockdown and replacement studies further supported kinase-independent scaffold functions for IRAK1 and IRAK4. These findings motivated development of JH-XIII-05-01, a first-in-class dual IRAK1/IRAK4 degrader designed to eliminate both catalytic and scaffold-dependent IRAK signaling. JH-XIII-05-01 retained potent IRAK1/IRAK4 biochemical activity, induced degradation of both targets, and showed superior antiproliferative activity compared with its nondegrading parental inhibitor JH-XI-82-01. JH-XIII-05-01 also enhanced apoptosis and synergized with covalent and noncovalent BTK inhibitors, BTK degraders, and the BCL-2 inhibitor venetoclax. These findings support dual IRAK1/IRAK4 degradation as a strategy for targeting MYD88 mutant lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.